Evidence map›Paper›PMID 39135188›Full record

ReviewStem cell research & therapy2024

Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.

Faezeh Ghanbari Sevari, Amir Mehdizadeh, Khadijeh Abbasi, Seyyed Sina Hejazian, Mortaza Raeisi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Faezeh Ghanbari SevariHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0002-7913-7514
Amir MehdizadehHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0002-3029-4172
Khadijeh AbbasiDepartment of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Seyyed Sina HejazianNeuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. hejazians@tbzmed.ac.ir.ORCID 0000-0002-8448-1539
Mortaza RaeisiHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. raiisy@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytokine-induced killer (CIK) cells are a novel subgroup of immune effectors, classified as one of the modified T cell-mediated arms for immunotherapy. These cells exert MHC-unrestricted cytotoxicity against both hematological and solid malignancies with low incidence of treatment-related severe complications. This study reviews the application of CIK cells in treating cases with hematologic malignancies. MAIN BODY: CIK cells consist of CD3

conclusionCIK cells have shown promising results in the treatment of hematologic malignancies, especially in combination with other antitumor strategies. However, the existing controversies in achieving desired clinical responses underscore the importance of future studies.

Indexed as

Cytokine-Induced Killer CellsHematologic NeoplasmsHumansImmunotherapyImmunotherapy, AdoptiveCancerCIK cellHematologic malignanciesTherapy

Identifiers

PMID39135188
PMCPMC11321231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.